DSIP has no single legal status. It depends on the product and how it is supplied.
No FDA-approved U.S. product; the July 2026 advisory vote did not add DSIP to the 503A list. A research use only label does not make a product approved for people.
Pharmacy mixing (compounding): FDA had placed it in Category 2 for possible safety risks, and the request was then withdrawn (FDA page dated April 22, 2026).
Sports: we have no current sports-rule review for it yet.
Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
This is not legal advice.
Whether you may buy, sell, or use a product also depends on pharmacy (compounding) rules, a prescription, and state law. Read how U.S. peptide law works.
The record found no FDA-approved product. A label that says research use only does not make a product approved for people.
What the record says: No FDA-approved U.S. product; the July 2026 advisory vote did not add DSIP to the 503A list
Is it on FDA's compounding safety list?
Nomination withdrawn
Listed as emideltide (DSIP).
FDA had placed it in Category 2 for possible safety risks. The person who asked FDA to allow it in compounding then withdrew the request. FDA still lists its safety concerns and has not made a final decision. A withdrawn request is neither a ban nor an approval.